peglmolesatide + roxadustat

This drug is a **combination therapy** of peglmolesatide and roxadustat. Roxadustat is a **hypoxia-inducible factor prolyl hydroxylase inhibitor** (HIF-PHI) that increases endogenous erythropoietin, promoting erythropoiesis and improving anemia in patients with chronic kidney disease (CKD)[1][2][3][4][6]. Its mechanism involves inhibiting prolyl hydroxylase, leading to stabilization of HIF-α subunits, upregulation of erythropoietin, improved iron utilization, and reduced hepcidin[1][2][3][4][6][8]. Peglmolesatide is a pegylated synthetic peptide analog of erythropoietin, engineered to stimulate erythropoiesis as a long-acting erythropoiesis-stimulating agent (ESA) (from general knowledge; peglmolesatide is not mentioned in the search results but is known as a next-generation ESA for anemia). The **combination** is conceptually intended to enhance erythropoietic response in CKD-associated anemia, especially in patients with hyporesponsiveness to standard ESAs.